Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt No Debt
SYN's Cash-to-Debt is ranked higher than
90% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. SYN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SYN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
SYN's Interest Coverage is ranked higher than
93% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SYN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SYN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -40.23
Beneish M-Score: -30.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -389.85
SYN's ROE % is ranked lower than
97% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. SYN: -389.85 )
Ranked among companies with meaningful ROE % only.
SYN' s ROE % Range Over the Past 10 Years
Min: -389.85  Med: -120.46 Max: -48.04
Current: -389.85
-389.85
-48.04
ROA % -148.43
SYN's ROA % is ranked lower than
90% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. SYN: -148.43 )
Ranked among companies with meaningful ROA % only.
SYN' s ROA % Range Over the Past 10 Years
Min: -174.99  Med: -79.33 Max: -41.8
Current: -148.43
-174.99
-41.8
ROC (Joel Greenblatt) % -7954.56
SYN's ROC (Joel Greenblatt) % is ranked lower than
86% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. SYN: -7954.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SYN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14661.9  Med: -915.08 Max: -112.64
Current: -7954.56
-14661.9
-112.64
3-Year EBITDA Growth Rate 0.90
SYN's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. SYN: 0.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SYN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 101.3
Current: 0.9
0
101.3
3-Year EPS without NRI Growth Rate 2.90
SYN's 3-Year EPS without NRI Growth Rate is ranked higher than
56% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SYN: 2.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SYN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 65.1
Current: 2.9
0
65.1
GuruFocus has detected 1 Warning Sign with Synthetic Biologics Inc $SYN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SYN's 10-Y Financials

Financials (Next Earnings Date: 2017-03-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SYN Guru Trades in Q1 2016

Ken Fisher 10,500 sh (unchged)
» More
Q2 2016

SYN Guru Trades in Q2 2016

Ken Fisher 25,000 sh (+138.10%)
» More
Q3 2016

SYN Guru Trades in Q3 2016

Ken Fisher 50,000 sh (+100.00%)
» More
Q4 2016

SYN Guru Trades in Q4 2016

Ken Fisher 133,967 sh (+167.93%)
» More
» Details

Insider Trades

Latest Guru Trades with SYN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:XXII, NAS:SNSS, NAS:ARQL, NAS:ECYT, OTCPK:HBPCF, NAS:CASI, OTCPK:ORGS, NAS:CASC, NAS:NEPT, AMEX:CRMD, OTCPK:PMCB, NAS:ORMP, NAS:VCEL, AMEX:ATNM, NAS:CRME, NAS:TTNP, NAS:GTXI, NAS:BCLI, NAS:IPCI, AMEX:NAVB » details
Traded in other countries:SFYB.Germany,
Synthetic Biologics Inc is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases.

Synthetic Biologics Inc was incorporated in 1986 as Sheffield Pharmaceuticals, Inc. The Company is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases. Its developing an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome or C-IBS, an oral biologic to protect the gastrointestinal or GI microflora from the effects of intravenous or IV antibiotics for the prevention of Clostridium difficile or C. diff infection, a series of monoclonal antibodies or mAbs for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, it has two legacy programs. Its developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis or MS and cognitive dysfunction in MS. It also partnered the development of a treatment for fibromyalgia. Trimesta or oral estriol is being developed as an oral once-daily treatment for relapsing-remitting MS in women. Trimesta is also being developed for the treatment of cognitive dysfunction in female MS patients. This 12-month randomized, double-blind, placebo-controlled Phase II clinical trial is being conducted at UCLA. There are nine FDA-approved therapies for the treatment of relapsing-remitting MS: Betaseron, Rebif, Avonex, Copaxone, Tysabri, Gilenya, Extavia, Aubagio and Tecfidera. Effirma or flupirtine is being developed for the treatment of fibromyalgia by Meda AB. Current FDA-approved therapies for the treatment of C-IBS include AMITIZA or lubiprostone and LINZESS or linaclotide. The Company utilizes contract manufacturing firms to produce its investigational products Trimesta and SYN-004 in accordance with current good manufacturing processes or cGMP guidelines outlined by the FDA. It competes with Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec, Eli Lilly & Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck & Co., Pfizer, Novartis, Teva Pharmaceuticals and United Therapeutics, among others. The Company is subject to various government FDA, FTC, CPSC and USDA regulations.

Ratios

vs
industry
vs
history
Current Ratio 0.55
SYN's Current Ratio is ranked lower than
91% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. SYN: 0.55 )
Ranked among companies with meaningful Current Ratio only.
SYN' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 5.25 Max: 58.44
Current: 0.55
0.03
58.44
Quick Ratio 0.55
SYN's Quick Ratio is ranked lower than
89% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. SYN: 0.55 )
Ranked among companies with meaningful Quick Ratio only.
SYN' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 5.41 Max: 58.44
Current: 0.55
0.03
58.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.00
SYN's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. SYN: -27.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SYN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35.4  Med: 0 Max: 0
Current: -27
-35.4
0

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -49.80
SYN's Earnings Yield (Greenblatt) % is ranked lower than
88% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. SYN: -49.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SYN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -65.11  Med: 0 Max: 0
Current: -49.8
-65.11
0

More Statistics

EPS (TTM) $ -0.43
Beta2.68
Short Percentage of Float12.37%
52-Week Range $0.73 - 2.74
Shares Outstanding (Mil)117.17

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.35 -0.43 -0.60 -0.59
EPS without NRI ($) -0.35 -0.43 -0.60 -0.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SYN

Headlines

Articles On GuruFocus.com
Synodon Inc. – A Breakthrough Technology For Pipeline Safety Jan 28 2013 

More From Other Websites
Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2,... Feb 21 2017
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 13 2017
Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference Feb 03 2017
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jan 19 2017
Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to... Jan 18 2017
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 09 2017
Synthetic Biologics C. Difficile Drug Trial Succeeds Jan 06 2017
Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C.... Jan 05 2017
Synthetic Biologics' C. difficile mid-stage study meets main goal Jan 05 2017
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 05 2017
Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C.... Jan 05 2017
Synthetic Biologics to Present at the Biotech Showcase™ 2017 Conference Jan 03 2017
Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed... Dec 13 2016
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Dec 02 2016
Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences Dec 01 2016
Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences Dec 01 2016
Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants Nov 18 2016
Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants Nov 18 2016
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Nov 15 2016
Nokia, Teva Plunge into Tuesday’s 52-Week Low Club Nov 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)